Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.43 |
| ▸ | CDK2 | P24941 | 18/20 | 0.43 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 12/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 12/20 | 0.42 |
| ▸ | CDK4 | P11802 | 7/20 | 0.42 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.41 |
| ▸ | CDK9 | P50750 | 6/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1391300 | 0.90 | CCNE1 (0.42) | CCNE1CDK2CCNE2CCND1CDK6 | |
| SCHEMBL1391933 | 0.84 | CCNE1 (0.44) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL1391898 | 0.84 | CDK2 (0.43) | CCNE1CDK2CCNE2CCND1CDK6 | |
| SCHEMBL1391974 | 0.82 | CDK2 (0.42) | CCNE1CDK2CCNE2CCND1CDK6 | |
| SCHEMBL1392662 | 0.82 | POLB (0.51) | CA1CA2CA9JAK3 | |
| SCHEMBL1391043 | 0.81 | EGFR (0.47) | CCNE1CDK2CCNE2CCND1CDK6 | |
| SCHEMBL1391784 | 0.80 | CCNE1 (0.46) | CCNE1CDK2CCNE2CCND1CDK6 | |
| SCHEMBL1392226 | 0.77 | MEN1 (0.45) | CCNE1CDK2CCNE2CCND1CDK6 | |
| SCHEMBL1392274 | 0.77 | IDH2 (0.43) | CCNE1CDK2CCND1CDK6CDK4 | |
| SCHEMBL1391161 | 0.77 | IDH2 (0.41) | CCNE1CDK2CCNE2CCND1CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2231624-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | Progenics Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009091388-A2 | TRIAZINES AND RELATED COMPOUNDS HAVING ANTIVIRAL ACTIVITY, COMPOSITIONS AND METHODS THEREOF | PROGENICS PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | CCNE1 1264/4885CDK2 585/4885CCNE2 2594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.